Get the Stockscreener App
61.12
0.91%
0.55
After Hours:
61.37
0.25
+0.41%
Biomarin Pharmaceutical Inc stock is traded at $61.12, with a volume of 2.63M.
It is up +0.91% in the last 24 hours and up +5.14% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$60.57
Open:
$60.23
24h Volume:
2.63M
Relative Volume:
1.08
Market Cap:
$11.75B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
22.72
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-0.99%
1M Performance:
+5.14%
6M Performance:
+5.80%
1Y Performance:
-14.17%
1-Day Range:
$59.16
$61.52
1-Week Range:
$58.50
$61.52
52-Week Range:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
61.12 | 11.65B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
(BMRN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Skeletal Dysplasia Market - GlobeNewswire Inc.
BioMarin Pharma: The Under-Two Strategy and New Market Ramps Shaping Voxzogo’s Next Chapter! - Smartkarma
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients - AOL.com
Elo Mutual Pension Insurance Co Boosts BioMarin Pharmaceutical Holdings - National Today
Elo Mutual Pension Insurance Co Purchases 22,851 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Barclays raises BioMarin stock price target to $105 on acquisition By Investing.com - Investing.com UK
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
The kids are alright: Old drug from BioMarin scores key win in teensSan Francisco Business Times - The Business Journals
Barclays raises BioMarin stock price target to $105 on acquisition - Investing.com
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients - Intellectia AI
Truist reiterates Buy on BioMarin stock amid new competition - Investing.com India
Truist reiterates Buy on BioMarin stock amid new competition By Investing.com - Investing.com Nigeria
BioMarin stock price target raised to $105 by Freedom Capital on margin outlook - Investing.com Nigeria
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
Cantor Fitzgerald reiterates Overweight on BioMarin stock at $85 - Investing.com
BioMarin Pharmaceutical Inc. $BMRN Holdings Cut by Rafferty Asset Management LLC - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
2 Reasons to Like BMRN (and 1 Not So Much) - Finviz
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98Here's Why - Bitget
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here’s Why - Yahoo Finance
Andra AP fonden Acquires 105,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
A Look At BioMarin (BMRN) Valuation After Recent Share Price Rebound And Undervaluation Debate - Sahm
Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why - Bitget
Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here’s Why - Insider Monkey
FDA clears PKU drug that lets some teens drop ultra-strict diets - Stock Titan
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) - PR Newswire
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Sahm
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds - Insider Monkey
BioMarin Pharmaceutical EVP Trades $381K In Company Stock - Benzinga
DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharm - GuruFocus
Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock - Investing.com
Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock By Investing.com - Investing.com Australia
Insider Selling: BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Sells 6,326 Shares of Stock - MarketBeat
Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares - Investing.com
Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares By Investing.com - Investing.com South Africa
BioMarin (BMRN) legal chief sells shares and earns performance RSUs - Stock Titan
BioMarin Pharmaceutical (BMRN) CFO earns multiple performance-based stock awards - Stock Titan
Brokered sale notice for BioMarin (NASDAQ: BMRN) tied to vesting and ESPP - Stock Titan
BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo - Yahoo Finance
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
Fidelity proposes sale of BMRN shares (NASDAQ: BMRN) — Form 144 notice - Stock Titan
Canaccord raises BioMarin stock price target to $104 on earnings - Investing.com
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Primecap Management Co. CA - MarketBeat
Boehringer drug approved in 44 days; BioMarin shelves Roctavian - BioPharma Dive
H.C. Wainwright cuts BioMarin stock price target on competition By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2025 Earnings Call Transcript - Insider Monkey
BioMarin Reports Mixed Q4 Results with Earnings Miss - Intellectia AI
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
2.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):